TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24770971

Group type: EXPERIMENTAL
Intervention: EUS-PCA with ethanol and paclitaxel
Number of subjects: 22
Study: 24771206

Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active painkillers followed by placebos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological factors and social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top-down systems for pain control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain imaging studies
Number of subjects: 0
Study: 24771350

Group type: EXPERIMENTAL
Intervention: ASP9521 (30 mg/day for 12 weeks)
Number of subjects: 13
Study: 24771806

Group type: EXPERIMENTAL
Intervention: Nexfin™ device
Number of subjects: 31
Study: 24772351

Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Number of subjects: 678

Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 678
Study: 24773774

Group type: EXPERIMENTAL
Intervention: Plasma samples using allele-specific PCR assays
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Biopsy samples using cobas(®) EGFR Tissue Test
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Matched pairs of plasma and biopsy samples
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Plasma samples
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Plasma and biopsy tissue comparison
Number of subjects: 199
Study: 24773782

Group type: EXPERIMENTAL
Intervention: Anti-HEV IgG antibodies
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Recent HEV infection
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: HEV RNA detection
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Markers of HEV infection
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Evidence of recent infection (acute on chronic) liver disease
Number of subjects: 166
Study: 24774037

Group type: EXPERIMENTAL
Intervention: Ganglion excision and decompression of Guyon's canal
Number of subjects: 9
Study: 24774647

Group type: EXPERIMENTAL
Intervention: Plasma folate concentrations
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Plasma vitamin B12 concentrations
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Folate increase
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: EPDS scores
Number of subjects: 709
Study: 24775515

Group type: EXPERIMENTAL
Intervention: Travelers who acquired multiresistant Enterobacteriaceae
Number of subjects: 2216
Study: 24777136

Group type: EXPERIMENTAL
Intervention: Antiepileptic medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epilepsy surgery (selective amygdalohippocampectomy, temporal lobe resection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotactic radiofrequency amygdalohippocampectomy and hippocampal stimulation
Number of subjects: 0
Study: 24777247

Group type: EXPERIMENTAL
Intervention: Autologous T cells electroporated with mRNA coding for CAR
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Repeated infusions of CAR-T cells
Number of subjects: 4
Study: 24777501

Group type: EXPERIMENTAL
Intervention: (124)I-labeled L19SIP (immuno-PET imaging)
Number of subjects: 6
Study: 24777716

Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks, 900 mg in week 5, and 900 mg every 2 weeks thereafter)
Number of subjects: 7
Study: 24777850

Group type: EXPERIMENTAL
Intervention: Preconception prediction model for gestational diabetes mellitus (GDM)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes in women with PCOS
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Maternal complications during pregnancy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Neonatal complications
Number of subjects: 326
Study: 24778397

Group type: EXPERIMENTAL
Intervention: HPV-OPC patients
Number of subjects: 164

Group type: COMPARATOR
Intervention: Partners of HPV-OPC patients
Number of subjects: 164
Study: 24780049

Group type: EXPERIMENTAL
Intervention: Circulating irisin levels in BAT-positive women
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Circulating irisin levels in individuals with sarcopenia
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Circulating irisin levels in individuals defined by ASM/height(2)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Circulating irisin levels in individuals with detectable BAT
Number of subjects: 401

Group type: COMPARATOR
Intervention: Circulating irisin levels in individuals with sarcopenia compared to control subjects
Number of subjects: 401
Study: 24780882

Group type: EXPERIMENTAL
Intervention: Expanded allele size for SCA2 and SCA3 genotypes
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Expanded allele size for SCA1 and SCA6 genotypes
Number of subjects: 1310

Group type: EXPERIMENTAL
Intervention: Normal allele size for SCA1 and SCA6 genotypes
Number of subjects: 1310
Study: 24780907

Group type: EXPERIMENTAL
Intervention: Exercise testing in patients with mild-to-moderate PV stenosis
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Linear increase of peak PV gradient with increasing flow
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oxygen pulse-workload relationship
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Right heart morphology and function assessment
Number of subjects: 19
Study: 24780909

Group type: EXPERIMENTAL
Intervention: Aortic valve area (AVA) adjusted by body surface area (BSA)
Number of subjects: 2843

Group type: COMPARATOR
Intervention: Aortic valve area (AVA)
Number of subjects: 2843
Study: 24781896

Group type: EXPERIMENTAL
Intervention: Progressive Aerobic Cardiovascular Endurance Run (PACER) laps (aerobic fitness)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Fitness (measured by PACER)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 687
Study: 24782475

Group type: EXPERIMENTAL
Intervention: Posterior iris-claw aphakic IOL implantation and DMEK
Number of subjects: 7
Study: 24782509

Group type: EXPERIMENTAL
Intervention: CAR.CD19-T cells expanded ex vivo using IL-2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Culturing CAR-T cells with IL-7 and IL-15
Number of subjects: 14
Study: 24782549

Group type: EXPERIMENTAL
Intervention: Unidirectional breathing (UB)
Number of subjects: 16
Study: 24782620

Group type: EXPERIMENTAL
Intervention: Hansenula-derived PEGylated interferon alpha-2a plus ribavirin for 12 weeks (weekly subcutaneous injection of PEG-IFN-alpha-2a plus daily oral ribavirin).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Extended treatment course up to 72 weeks for patients who were PCR-negative at week 48 but had at least one PCR-positive test during therapy.
Number of subjects: 46

Group type: COMPARATOR
Intervention: 5-day treatment schedule of PEG-IFN-alpha-2a plus ribavirin.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Factors related to better response: male gender, short duration of infection, low viral load, mild activity, and mild fibrosis.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Assessment of liver transaminases before and after treatment.
Number of subjects: 46
Study: 24782684

Group type: EXPERIMENTAL
Intervention: HMBFA-HIIT (3 g per day of HMBFA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: PLA-HIIT
Number of subjects: 34

Group type: COMPARATOR
Intervention: CTL
Number of subjects: 34
Study: 24784775

Group type: EXPERIMENTAL
Intervention: NACRT
Number of subjects: 27
Study: 24786393

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy (IST) consisting of antithymocyte globulin and cyclosporine A in 28 patients
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TCRVβ skewing in 40% of RCC patients
Number of subjects: 92
Study: 24786594

Group type: EXPERIMENTAL
Intervention: Feeling Thermometer (patient-reported health status instrument)
Number of subjects: 408
Study: 24786603

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg BID) combined with radiation therapy (60 Gy in 2 Gy fractions) and temozolomide (75 mg/m² daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg BID) combined with radiation therapy and temozolomide
Number of subjects: 17

Group type: COMPARATOR
Intervention: Temozolomide alone
Number of subjects: 17
Study: 24786834

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2936

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2936

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2936

Group type: EXPERIMENTAL
Intervention: Canagliflozin (both doses)
Number of subjects: 2936
Study: 24786929

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg intravenously every 2 weeks
Number of subjects: 40
Study: 24787738

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (500 mg, once daily) for 1 or 2 days followed by oral azithromycin (250 mg once daily) to complete a total of 7 days treatment
Number of subjects: 60
Study: 24788740

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 24788804

Group type: EXPERIMENTAL
Intervention: Patient Empowerment Programme (PEP)
Number of subjects: 1141

Group type: COMPARATOR
Intervention: non-PEP group
Number of subjects: 1141
Study: 24788898

Group type: EXPERIMENTAL
Intervention: PrePex device
Number of subjects: 427
Study: 24788983

Group type: EXPERIMENTAL
Intervention: Sun protection education workbook with pictures of skin cancer on varying skin tones
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Revised workbook including pictures of squamous cell carcinoma
Number of subjects: 24
Study: 24789707

Group type: EXPERIMENTAL
Intervention: Functional T lesion (insufficient collateral flow to ipsilateral anterior cerebral arteries via contralateral ICA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Functional L lesion
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Functional I lesion
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall clinical outcomes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clots categorized as I lesion
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clots categorized as L lesion
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Clots categorized as T lesion
Number of subjects: 72
Study: 24789750

Group type: EXPERIMENTAL
Intervention: Endovenous cyanoacrylate-based embolization
Number of subjects: 38
Study: 24790273

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea syndrome (OSAS) screening using ≥ 3/h total sleep time (TST) as the cutoff.
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Mean respiratory disturbance index (RDI) assessment.
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Mean obstructive RDI (ORDI) assessment.
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Mean obstructive apnea-hypopnea index (OAHI) assessment.
Number of subjects: 248
Study: 24790820

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LFD)
Number of subjects: 79
Study: 24792486

Group type: EXPERIMENTAL
Intervention: Brainstem biopsy
Number of subjects: 0
Study: 24793253

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes at hospital discharge using SF-12, Hospital Anxiety and Depression Scale, EQ-5D, Brief Illness Perception Questionnaire (B-IPQ), HeartQoL, and Edmonton Symptom Assessment Scale.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes at baseline.
Number of subjects: 0
Study: 24794216

Group type: EXPERIMENTAL
Intervention: High on-clopidogrel platelet reactivity (OCR)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: High on-aspirin platelet reactivity (OAR)
Number of subjects: 1001

Group type: COMPARATOR
Intervention: High vs. normal on-treatment platelet reactivity
Number of subjects: 1001
Study: 24794806

Group type: EXPERIMENTAL
Intervention: SAR103168, a novel multi-targeted kinase inhibitor
Number of subjects: 29
Study: 24794816

Group type: EXPERIMENTAL
Intervention: Nicotinamide (2-8 g oral) for 5 days and 8 weeks, with doses gradually escalated during phases 1 and 2.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide (3.5-6 g daily) for 8 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide (high-dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Number of subjects: 0
Study: 24794878

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 24795390

Group type: EXPERIMENTAL
Intervention: Protein farnesylation inhibitors (treated group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Untreated cohort (control group)
Number of subjects: 86
Study: 24795473

Group type: EXPERIMENTAL
Intervention: Higher IL-6 level at year 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher sTNFR-I level at year 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher sTNFR-II level at year 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher KT ratio at year 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher D-dimer level at year 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarker values at baseline and pre-event time points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-cell activation
Number of subjects: 0
Study: 24795483

Group type: EXPERIMENTAL
Intervention: Experimental hookworm infection with Necator americanus
Number of subjects: 0
Study: 24796940

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 40
Study: 24797180

Group type: EXPERIMENTAL
Intervention: Reduced-toxicity conditioning (RTC) regimen of BU 12.8-16 mg/kg, fludarabine 180 mg/m², alemtuzumab 54 mg/m² (BFA) before HLA-matched sibling donor transplantation
Number of subjects: 18
Study: 24797299

Group type: EXPERIMENTAL
Intervention: Comprehensive prognostic index based on 8 independent predictors of overall survival (OS) including sex, age, ECOG status, del(17p), del(11q), IGHV mutation status, serum β2-microglobulin, and serum thymidine kinase.
Number of subjects: 1948

Group type: EXPERIMENTAL
Intervention: Prognostic index validated in a series of 676 newly diagnosed CLL patients from Mayo Clinic.
Number of subjects: 1948
Study: 24797373

Group type: EXPERIMENTAL
Intervention: Activities of spiritual care providers (supporting religious and spiritual needs, providing support for family feelings)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Activities of spiritual care providers (discussions about patient's end-of-life wishes, preparation for family conference, total number of activities performed)
Number of subjects: 275
Study: 24798021

Group type: EXPERIMENTAL
Intervention: Oral posaconazole with intravenous micafungin bridging (POS-MIC)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Oral posaconazole (POS)
Number of subjects: 212
Study: 24799460

Group type: EXPERIMENTAL
Intervention: HPV-positive patients
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: p16-positive patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: HPV-negative patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: p16-negative patients
Number of subjects: 64

Group type: COMPARATOR
Intervention: Loss of ≥5% weight in previous 6 months
Number of subjects: 64
Study: 24799481

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with rituximab and anthracycline
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Residual uptake higher than MBP but below liver uptake
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Using liver uptake as cutoff for PET positivity
Number of subjects: 125
Study: 24800110

Group type: EXPERIMENTAL
Intervention: CATCH-IT intervention (motivational interview + Internet program)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CATCH-IT intervention (brief advice + Internet program)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: CATCH-IT intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 24800123

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24800949

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m², Pazopanib 400 mg, Lapatinib 1000 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m² with Pazopanib 400 mg and Lapatinib 1000 mg
Number of subjects: 26
Study: 24801171

Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 20
Study: 24801350

Group type: EXPERIMENTAL
Intervention: Fully covered self-expanding metal stents (FCSEMS)
Number of subjects: 187
Study: 24801465

Group type: EXPERIMENTAL
Intervention: Higher zinc and copper concentrations in cord blood
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lower activity of glutathione peroxidase enzyme 3 in umbilical cord blood plasma
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Vitamin A and E concentrations in plasma
Number of subjects: 240
Study: 24801544

Group type: EXPERIMENTAL
Intervention: Bio-inspired artificial pancreas (BiAP) system during fasting study
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bio-inspired artificial pancreas (BiAP) system during overnight/postprandial study
Number of subjects: 20
Study: 24801836

Group type: EXPERIMENTAL
Intervention: Intratumoral and intramuscular injections of polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose (poly-ICLC)
Number of subjects: 1
Study: 24802773

Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg, days 5-32) + Dexamethasone (40 mg by mouth, days 1-4)
Number of subjects: 12
Study: 24805101

Group type: EXPERIMENTAL
Intervention: Stimulation with anti-CD3
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Unstimulated lung CD4+ T cells
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall analysis of subjects
Number of subjects: 53
Study: 24807459

Group type: EXPERIMENTAL
Intervention: Linifanib (7.5 mg and 12.5 mg) in combination with carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m²)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Linifanib (12.5 mg)
Number of subjects: 12
Study: 24807889

Group type: EXPERIMENTAL
Intervention: VTX-2337 (0.1-3.9 mg/m(2)) administered subcutaneously on days 1, 8, and 15 of each 28-day cycle
Number of subjects: 33
Study: 24808483

Group type: EXPERIMENTAL
Intervention: Nutritional intake with a higher protein:energy ratio at days 10 and 21
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid treatment
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Initial growth and quality of nutrition
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Gestational and postnatal ages
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Growth between birth and day 5 and growth between day 5 and discharge
Number of subjects: 141

Group type: COMPARATOR
Intervention: Comparison of FFM with reference data in term infants
Number of subjects: 141
Study: 24809540

Group type: EXPERIMENTAL
Intervention: Surgical intervention for occlusal caries in adult patients
Number of subjects: 282

Group type: COMPARATOR
Intervention: Surgical intervention for occlusal caries in pediatric patients
Number of subjects: 282
Study: 24809761

Group type: EXPERIMENTAL
Intervention: Moderate CRF
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: High CRF
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: High CRF after adjustment for MVPA
Number of subjects: 423

Group type: COMPARATOR
Intervention: Low CRF
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 423
Study: 24811751

Group type: EXPERIMENTAL
Intervention: varenicline (0.25 mg BID, 0.5 mg BID, 1 mg BID)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Maximum CA of 4 to 6 weeks
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Participants aged 21-34 years
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: MNWS urge to smoke score of 2 to 4
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Having made ≥ 1 serious quit attempts
Number of subjects: 277
Study: 24811754

Group type: EXPERIMENTAL
Intervention: SC serum-free interferon β-1a 44 μg or 22 μg 3 times weekly for 12 months
Number of subjects: 251
Study: 24811995

Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Crohn's Disease (CD)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis (UC)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Pouchitis
Number of subjects: 204
Study: 24812403

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of tumor-infiltrating lymphocytes (TIL) containing about 25% mutation-specific polyfunctional T(H)1 cells
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Retreatment with >95% pure population of mutation-reactive T(H)1 cells
Number of subjects: 1
Study: 24812407

Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-positive men
Number of subjects: 9342

Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-negative men
Number of subjects: 9342

Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-positive men (PCR-based studies)
Number of subjects: 9342

Group type: EXPERIMENTAL
Intervention: Any HPV among HIV-negative men (PCR-based studies)
Number of subjects: 9342
Study: 24813429

Group type: EXPERIMENTAL
Intervention: IBS-QOL questionnaire using the testlet response model (TRM)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: IBS-QOL questionnaire using the constrained graded response model (CGRM)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: IBS-QOL questionnaire using the unconstrained graded response model (UGRM)
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: IBS-QOL total score
Number of subjects: 753
Study: 24814215

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (42 healthy full-term infants)
Number of subjects: 52
Study: 24814497

Group type: EXPERIMENTAL
Intervention: Clinical classification of AF (paroxysmal or persistent) by physicians at baseline
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Higher ejection fraction
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Presence of coronary artery disease
Number of subjects: 1195
Study: 24814582

Group type: EXPERIMENTAL
Intervention: Patient education programme
Number of subjects: 0
Study: 24814620

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (Cervarix©)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Aluminium hydroxide (ALU group)
Number of subjects: 271